Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 50

1.

HIV entry inhibitors in clinical development.

O'Hara BM, Olson WC.

Curr Opin Pharmacol. 2002 Oct;2(5):523-8. Review.

PMID:
12324253
2.

Emerging drug targets for antiretroviral therapy.

Reeves JD, Piefer AJ.

Drugs. 2005;65(13):1747-66. Review.

PMID:
16114975
3.

Opportunities and challenges in targeting HIV entry.

Biscone MJ, Pierson TC, Doms RW.

Curr Opin Pharmacol. 2002 Oct;2(5):529-33. Review.

PMID:
12324254
4.

HIV-1 entry inhibitors: classes, applications and factors affecting potency.

Sterjovski J, Churchill MJ, Wesselingh SL, Gorry PR.

Curr HIV Res. 2006 Oct;4(4):387-400. Review.

PMID:
17073614
5.

The HIV entry inhibitors revisited.

Leonard JT, Roy K.

Curr Med Chem. 2006;13(8):911-34. Review.

PMID:
16611075
7.

HIV-1 cell entry and advances in viral entry inhibitor therapy.

Cooley LA, Lewin SR.

J Clin Virol. 2003 Feb;26(2):121-32. Review.

PMID:
12600644
8.

Virus entry as a target for anti-HIV intervention.

Esté JA.

Curr Med Chem. 2003 Sep;10(17):1617-32. Review.

PMID:
12871111
9.

The current status of, and challenges in, the development of CCR5 inhibitors as therapeutics for HIV-1 infection.

Maeda K, Nakata H, Ogata H, Koh Y, Miyakawa T, Mitsuya H.

Curr Opin Pharmacol. 2004 Oct;4(5):447-52. Review.

PMID:
15351348
10.

The appealing story of HIV entry inhibitors : from discovery of biological mechanisms to drug development.

Castagna A, Biswas P, Beretta A, Lazzarin A.

Drugs. 2005;65(7):879-904.

PMID:
15892586
11.

HIV-1 entry inhibitors: closing the front door.

Tomkowicz B, Collman RG.

Expert Opin Ther Targets. 2004 Apr;8(2):65-78. Review.

PMID:
15102550
12.

Potential drug targets on the HIV-1 envelope glycoproteins, gp120 and gp41.

Huang L, Zhang L, Chen CH.

Curr Pharm Des. 2003;9(18):1453-62. Review.

PMID:
12769725
13.

Evaluation of current approaches to inhibit HIV entry.

Pöhlmann S, Doms RW.

Curr Drug Targets Infect Disord. 2002 Mar;2(1):9-16. Review.

PMID:
12462149
14.

Clinical development of microbicides for the prevention of HIV infection.

D'Cruz OJ, Uckun FM.

Curr Pharm Des. 2004;10(3):315-36. Review.

PMID:
14754390
15.

Prospects of HIV-1 entry inhibitors as novel therapeutics.

Pierson TC, Doms RW, Pöhlmann S.

Rev Med Virol. 2004 Jul-Aug;14(4):255-70. Review.

PMID:
15248253
16.

HIV-1 gp41: mediator of fusion and target for inhibition.

Weiss CD.

AIDS Rev. 2003 Oct-Dec;5(4):214-21. Review.

PMID:
15012000
17.

New advances in HIV entry inhibitors development.

Rusconi S, Scozzafava A, Mastrolorenzo A, Supuran CT.

Curr Drug Targets Infect Disord. 2004 Dec;4(4):339-55. Review.

PMID:
15578975
18.
19.

HIV-1 gp41 as a target for viral entry inhibition.

Root MJ, Steger HK.

Curr Pharm Des. 2004;10(15):1805-25. Review.

PMID:
15180542
20.

[Chemokine receptors and its importance in the replication cycle of human immunodeficiency virus: clinical and therapeutic implications].

Azevedo-Pereira JM, Santos-Costa Q.

Acta Med Port. 2008 Sep-Oct;21(5):497-504. Epub 2009 Jan 16. Review. Portuguese.

Supplemental Content

Support Center